BETA / NSE / Biotechnology & Drugs
Beta Drugs
1Y Price Trend
Key Information
Recommendations
Target High2,000
Target Low990.1
Target Mean0
Target Median0
Risk Metrics
StatusNot available
Key Analysis
Overall score, performance score, return rating, defensive, aggressive, and balanced views.
Download appProjection Analytics
Best-case, base-case, worst-case, and dynamic AI projection views.
Download appLatest stock news
Beta Drugs Ltd Locks at Upper Circuit With 19.4% Gain — Buyers Queue, Sellers Absent MarketsMojo
Beta Drugs Ltd Valuation Shifts to Very Expensive Amidst Strong Price Gains MarketsMojo
Ashish Kacholia Stocks: How Did the Ace Investor’s Top Holdings Perform in Q4? Trade Brains
Parabilis prices IPO at an ambitious $475 million pharmaphorum
Beta Drugs Q4 Results 2026 - Find Beta Drugs Q4 Earnings Result | BETA Q4 results Mint
Novel antibiotic Zaynich brings relief to the drought in antibiotic innovation Down To Earth
Beta Drugs Ltd is Rated Sell by MarketsMOJO Markets Mojo
Beta Drugs completes Nivian Lifesciences acquisition scanx.trade
© SharekeyX | Rusaka Technologies 2024-2026

